Compare Air Products & Chemicals, Inc. (APD) vs Biogen Inc (BIIB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Air Products & Chemicals, Inc. vs Biogen Inc — how do they compare? Air Products & Chemicals, Inc. trades at $305.84 (market cap $68.88B), while Biogen Inc trades at $206.31 (market cap $30.13B). The key difference: Air Products & Chemicals, Inc. is far larger — about 2.3× Biogen Inc's market cap, and Air Products & Chemicals, Inc. pays a 2.34% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| APD | BIIB | |
|---|---|---|
Market Cap | $68.88B | $30.13B |
Sector | Basic Materials | Health |
52-Week High | $314.19 | $216.63 |
52-Week Low | $230.42 | $128.93 |
Enterprise Value | $86.06B | $37.20B |
Dividend Yield | 2.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
APD trades at $305.54, down 0.86% on the day, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q3 2026 EPS of $3.47, exceeding expectations, and secured a long-term semiconductor supply deal in Taiwan. However, negative net income margin and elevated debt levels present fundamental concerns.
The stock offers upside to the $346 consensus price target, driven by volume growth and strategic contracts, but faces risks from high valuation multiples and leverage. Investor sentiment is positive amid raised guidance, though profitability challenges warrant caution.
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Air Products & Chemicals, Inc.
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $10.3 billion in revenue in fiscal 2021.
Read more on APD →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
